Zeeland Investment fund
Edisonweg 37 D1, Vlissingen, Zeeland, 4382 NV, The Netherlands
Overview
The regional development company Economic Pulse Zealand, the ZIGZAG foundation and a number of private investors are shareholders in the Zeeland Investment. They are connected in that they all have a link with Zeeland. They are living in New Zealand, his practice there (were) or have their roots. The shareholders invest not only capital but also by providing their knowledge, expertise and networks. Their broad expertise they have gained from the various leading positions in the (inter) national business. The performance of daily activities is in the hands of the fund manager, Johan Sebregts. Johan has extensive experience in retail and wholesale. Since 2003, he has led Starterslift Foundation, an organization in the southern Netherlands that focuses on supporting entrepreneurs in the early stages of their business. In addition, he has specialized in techno, and in particular the financing of these enterprises.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
Investment portfolio
- Toxys
Participated · Equity · Mar 2020
Toxys is a Leiden, The Netherlands-based biotech that develops animal-free mechanistic in vitro safety tests, led by CEO Giel Hendriks. Its patented ToxTracker® assay can identify toxic and carcinogenic properties of novel pharmaceuticals, agrochemicals and fine chemicals at early development stages. The company provides expert mechanistic in vitro chemical safety testing services for medicines, chemicals and consumer products. ToxTracker® is currently under review by international authorities for potential official acceptance and inclusion within standard regulatory safety test strategies. Toxys intends to use new funding to expand operations in Europe and the United States, broaden its portfolio of in vitro toxicology assays, and speed up international growth. The company plans to work on acceptance and implementation of its assays for regulatory applications.
- Mimetas
Participated · Equity · Oct 2014
Mimetas develops organ-on-a-chip products and tissue models, centered on its OrganoPlate® platform which supports 3D cell culture under continuous perfusion with membrane-free co-culture and epithelial and endothelial tubules. The company develops and validates customized disease, toxicology and transport models and has models for the kidney, liver, gut, brain and a range of oncological applications. Since its commercial launch in 2014 it has grown its customer base to half of the global top-50 pharmaceutical companies and also serves chemical, food and consumer goods firms; it also has operations in Japan. Mimetas was co-founded by Jos Joore and Paul Vulto. The company will use the proceeds from the recent financing to expand its global commercial presence with the OrganoPlate® platform, broaden its product portfolio, establish tissue production facilities, develop novel OrganoPlate® products and expand into clinical market segments, including personalized medicine. Mimetas recently raised a Series B financing to support these plans. Mimetas B.V. is a Leiden, The Netherlands-based developer of organ-on-a-chip technology. Led by co-founder and Chief Business Officer Jos Joore, the company develops predictive Organ-on-a-Chip cell culture models for tailored medicines. Its OrganoPlates™ feature organotypic screening models that can be screened at high throughput. Mimetas has a range of disease, toxicology and ADME models in its pipeline in various stages of development and validation. The company raised $5.2m in funding from Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost), which joined forces with national and regional partners. It intends to use the funds for development and sales of its 3D disease- and tissue-modelling technologies.
Team
No current team members are available.